Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | LCK | P06239 | 3/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876702 | 0.76 | MAPT (0.49) | LMNAMAPTLCKGAACSNK1D | |
| SCHEMBL3509164 | 0.68 | LCK (0.41) | PPARALMNAMAPTLCKKDM4E | |
| SCHEMBL4873810 | 0.67 | MLYCD (0.47) | LMNAMAPTTDP1GAAPOLB | |
| SCHEMBL28889077 | 0.66 | LCK (0.43) | PPARDPPARALCKGAARAB9A | |
| SCHEMBL440957 | 0.65 | LMNA (0.59) | LMNAMAPTGAAPOLBKDM4E | |
| SCHEMBL26388177 | 0.65 | LMNA (0.52) | LMNAMAPTGAATSHRABL1 | |
| SCHEMBL24071098 | 0.64 | ABL1 (0.48) | LMNALCKPOLBRAB9AABL1 | |
| SCHEMBL3509100 | 0.64 | LCK (0.46) | LCKALDH1A1 | |
| SCHEMBL28254309 | 0.64 | LMNA (0.46) | PPARDPPARALMNAMAPTLCK | |
| SCHEMBL28889083 | 0.64 | GCK (0.45) | LCKKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076771-A1 | Thrombopoietin Receptor Agonists | REITER LAWRENCE A | 2008-03-27 | — | — | US | disclosed |
| EP-1794156-A2 | TROMBOPOIETIN RECEPTOR AGONISTS | Pfizer Products Incorporated (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006033005-A2 | THROMBOPOIETIN RECEPTOR AGONISTS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076771-A1 | Thrombopoietin Receptor Agonists | MPL, THPO, TBXA2R | PPARD 411/4885PPARA 495/4885LMNA 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.